Oncologic drug development needs to place a greater focus on the patient, according to a commentary in the current issue of the New England Journal of Medicine. Even though the US Food and Drug ...
In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work ...
Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback